Admera Health's PGxOne™ Plus pharmacogenomics test helps analyze the genes linked to adverse drug reactions
MOUNTAIN VIEW, California, March 15, 2016 /PRNewswire/ -- Based on its recent analysis of the market for next-generation sequencing (NGS) molecular diagnostics, Frost & Sullivan recognizes Admera Health with the 2016 North American Frost & Sullivan Award for Technology Innovation. Admera has earned this honor for delivering a range of molecular tests, including the PGxOne™ Plus, CardioGxOne™, and oncology tests, for use across the entire continuum of patient care (screening, diagnosis, treatment, monitoring, and patient management).
Admera's flagship pharmacogenomics test, PGxOne™ Plus, enables the comprehensive analysis of 196 variants in 25 genes that can influence how a patient responds to specific drugs. Based on a patient's genetic makeup, the PGxOne™ Plus report provides recommendations for more than 150 commercial drugs prescribed for pain management, cardiovascular disease, psychiatry, cancer, and other indications.
"The PGxOne™ Plus report presents detailed patient-specific drug recommendations, such as whether a dosage should be altered or a completely different therapy should be prescribed. Valuable information about potentially harmful drug-drug interactions is also included," said Frost & Sullivan Senior Research Analyst Madhumitha Rangesa. "The clinically relevant results can help guide treatment decisions, which can potentially improve patient care and reduce adverse drug events."
Meanwhile, Admera's genetic testing for inherited cardiovascular diseases, CardioGxOne™, provides clear interpretation for risk assessment and disease diagnosis. The company's cancer testing offerings include the OncoGxOne™ and OncoGxSelect™. The former is a comprehensive cancer panel that detects a range of genomic variations related to targeted therapies and chemotherapeutic response across multiple cancer types, whereas the latter focuses on well-established and medically actionable mutations found in lung cancer.
In addition to these products, the company is creating multiple solutions with high commercialization potential. For instance, it recently announced the launch of AtheroGxOne™, a gene panel specifically for the risk assessment and diagnosis of premature coronary or atherosclerotic disease. Similarly, Admera has developed non-invasive cancer mutation detection technology from circulating tumor DNA (ctDNA) to guide cancer treatment selection and monitoring.
"Furthermore, Admera Health has built a fully automated bioinformatics technology platform, enabling the company to be uniquely positioned to compete in the promising digital health management space," noted Rangesa. "Admera's multiple partnerships support its product marketing and distribution initiatives, as well as help it avail the services of healthcare client management experts."
Admera has partnered with WaferGen Biosystems, a company that focuses mainly on the development of innovative NGS solutions. Through this partnership, the company has been able to leverage WaferGen's target enrichment technology in its PGxOne™ Plus panel to offer complete coverage of the required genes. To enhance its growth and deliver a more scalable platform, it has also collaborated with hc1 Healthcare Relationship Cloud® as its CRM partner to systemize relationships.
Overall, for its wide product range and rapidly growing pipeline that will assist the healthcare system by reducing the overall cost burden, Frost & Sullivan is pleased to present Admera Health with the 2016 North American Frost & Sullivan Award for Technology Innovation.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
About Admera Health
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
P: 210. 247.3870
VP, Business Development
SOURCE Frost & Sullivan